Cipralisant

From WikiMD's Wellnesspedia

Cipralisant is a histamine antagonist that was developed by Sanofi-Aventis. It acts as an inverse agonist at the H3 receptor, and has stimulant and nootropic effects. Cipralisant was in clinical trials for the treatment of obesity and ADHD, but as of 2016, it is no longer under development.

Etymology[edit | edit source]

The name "Cipralisant" is derived from the name of the pharmaceutical company that developed it, Sanofi-Aventis, and the class of drugs it belongs to, histamine antagonists.

Pharmacology[edit | edit source]

Cipralisant is a selective H3 receptor inverse agonist. This means it binds to the H3 receptor and produces an effect opposite to that of an agonist. In the case of Cipralisant, this results in increased release of histamine, a neurotransmitter involved in regulating wakefulness and attention.

Clinical Trials[edit | edit source]

Cipralisant was in clinical trials for the treatment of obesity and ADHD. The drug showed promise in early trials, with patients showing improved cognitive function and weight loss. However, the development of the drug was discontinued for unknown reasons.

Related Terms[edit | edit source]

See Also[edit | edit source]


Cipralisant Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD